Historique
Bulletin de Périodique
Journal of Psychoactive Drugs , Vol.51, n°2 - April-June 2019 - 50th Anniversary: Psychedelic research today
Paru le :
01/06/2019
Année :
2019
Page(s) :
93-208
Langue(s) :
Anglais
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Note de contenu :
CONTENTS:
- The past and future of psychedelic science: An introduction to this issue. Doblin R.E., Christiansen M., Jerome L., Burge B., p. 93-97.
- The role of the Journal of Psychedelic Drugs in the evolution of psychedelic medicine. Smith D.E., p. 98-101.
- Psychedelics and Dying Care: A historical look at the relationship between psychedelics and palliative care. Dyck E., p. 102-107.
- Effects of the psychedelic amphetamine MDA (3,4-Methylenedioxyamphetamine) in healthy volunteers. Baggott M.J., Garrison K.J., Coyle J.R., Galloway G.P., Barnes A.J., Huestis M.A., et al., p. 108-117.
- Might microdosing psychedelics be safe and beneficial? An initial exploration. Fadiman J., Korb S., p. 118-122.
- Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. Mason N.L., Mischler E., Uthaug M.V., Kuypers K.P.C., p. 123-134.
- Ayahuasca and public health: Health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. Ona G., Kohek M., Massaguer T., Gomariz A., Jimenez D.F., Dos Santos R.G., et al., p. 135-145.
- Embracing neurodiversity in psychedelic science: A mixed-methods inquiry into the MDMA experiences of autistic adults. Danforth A.L., p. 146-154.
- Ibogaine and subjective experience: Transformative states and psychopharmacotherapy in the treatment of opioid use disorder. Brown T.K., Noller G.E., Denenberg J.O., p. 155-165.
- Combining cognitive-behavioral conjoint therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A case example. Wagner A.C., Mithoefer M.C., Mithoefer A.T., Monson C.M., p. 166-173.
- Psychedelic-assisted group therapy: A systematic review. Trope A., Anderson B.T., Hooker A.R., Glick G., Stauffer C., Woolley J.D., p. 174-188.
- Ketamine Assisted Psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Dore J., Turnipseed B., Dwyer S., Turnipseed A., Andries J., Ascani G., et al., p. 189-198.
- Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: Qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. Barone W., Beck J., Mitsunaga-Whitten M., Perl P., p. 199-208.
- The past and future of psychedelic science: An introduction to this issue. Doblin R.E., Christiansen M., Jerome L., Burge B., p. 93-97.
- The role of the Journal of Psychedelic Drugs in the evolution of psychedelic medicine. Smith D.E., p. 98-101.
- Psychedelics and Dying Care: A historical look at the relationship between psychedelics and palliative care. Dyck E., p. 102-107.
- Effects of the psychedelic amphetamine MDA (3,4-Methylenedioxyamphetamine) in healthy volunteers. Baggott M.J., Garrison K.J., Coyle J.R., Galloway G.P., Barnes A.J., Huestis M.A., et al., p. 108-117.
- Might microdosing psychedelics be safe and beneficial? An initial exploration. Fadiman J., Korb S., p. 118-122.
- Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. Mason N.L., Mischler E., Uthaug M.V., Kuypers K.P.C., p. 123-134.
- Ayahuasca and public health: Health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. Ona G., Kohek M., Massaguer T., Gomariz A., Jimenez D.F., Dos Santos R.G., et al., p. 135-145.
- Embracing neurodiversity in psychedelic science: A mixed-methods inquiry into the MDMA experiences of autistic adults. Danforth A.L., p. 146-154.
- Ibogaine and subjective experience: Transformative states and psychopharmacotherapy in the treatment of opioid use disorder. Brown T.K., Noller G.E., Denenberg J.O., p. 155-165.
- Combining cognitive-behavioral conjoint therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A case example. Wagner A.C., Mithoefer M.C., Mithoefer A.T., Monson C.M., p. 166-173.
- Psychedelic-assisted group therapy: A systematic review. Trope A., Anderson B.T., Hooker A.R., Glick G., Stauffer C., Woolley J.D., p. 174-188.
- Ketamine Assisted Psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Dore J., Turnipseed B., Dwyer S., Turnipseed A., Andries J., Ascani G., et al., p. 189-198.
- Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: Qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. Barone W., Beck J., Mitsunaga-Whitten M., Perl P., p. 199-208.
Cote :
Abonnement
Dépouillements
Ajouter le résultat à votre sélection
R. E. DOBLIN ;
M. CHRISTIANSEN ;
L. JEROME ;
B. BURGE
|
2019
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first[...]
M. J. BAGGOTT ;
K. J. GARRISON ;
J. R. COYLE ;
G. P. GALLOWAY ;
A. J. BARNES ;
M. A. HUESTIS ;
J. E. MENDELSON
|
2019
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Entactogens such as 3,4-Methylenedioxymethamphetamine (MDMA, "molly", "ecstasy") appear to have unusual, potentially therapeutic, emotional effects. Understanding their mechanisms can benefit from clinical experiments with related drugs. Yet the[...]
J. FADIMAN ;
S. KORB
|
2019
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration of the effects of "microdoses," comprising hundreds of lengthy descriptive reports, was undertake[...]
A. TROPE ;
B. T. ANDERSON ;
A. R. HOOKER ;
G. GLICK ;
C. STAUFFER ;
J. D. WOOLLEY
|
2019
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Contemporary research with classic psychedelic drugs (e.g., lysergic acid diethylamide (LSD) and psilocybin) is indebted to the twentieth-century researchers and clinicians who generated valuable clinical knowledge of these substances through ex[...]
J. DORE ;
B. TURNIPSEED ;
S. DWYER ;
A. TURNIPSEED ;
J. ANDRIES ;
G. ASCANI ;
C. MONNETTE ;
A. HUIDEKOPER ;
N. STRAUSS ;
P. WOLFSON
|
2019
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Dans Journal of Psychoactive Drugs (Vol.51, n°2, April-June 2019) Article : Périodique
Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resist[...]